It was also demonstrated that nintedanib attenuates pulmonary fibrosis by reducing the activation in Wnt3a-induced myofibroblast through suppressing SRC kinase activation (Li et al., 2020). The gene discussed is WNT3A; the disease is pulmonary fibrosis.